BRUKINSA Drug Patent Profile

Which patents cover Brukinsa, and what generic alternatives are available?

Brukinsa is a drug marketed by Beone Medicines Usa and is included in two NDAs. There are thirteen patents protecting this drug and two Paragraph IV challenges.

This drug has one hundred and five patent family members in thirty-two countries.

The generic ingredient in BRUKINSA is zanubrutinib. One supplier is listed for this compound. Additional details are available on the zanubrutinib profile page.

DrugPatentWatch^® Generic Entry Outlook for Brukinsa

Brukinsa was eligible for patent challenges on November 14, 2023.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be August 15, 2037. This may change due to patent challenges or generic licensing.

There are two Paragraph IV patent challenges for this drug. This may lead to patent invalidation or a license for generic production.

Indicators of Generic Entry

Summary for BRUKINSA

International Patents:	105
US Patents:	13
Applicants:	1
NDAs:	2

Paragraph IV (Patent) Challenges for BRUKINSA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
BRUKINSA	Tablets	zanubrutinib	160 mg	218785	1	2025-11-13
BRUKINSA	Capsules	zanubrutinib	80 mg	213217	2	2023-11-14

US Patents and Regulatory Information for BRUKINSA

BRUKINSA is protected by sixty-nine US patents and twelve FDA Regulatory Exclusivities.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Beone Medicines Usa	BRUKINSA	zanubrutinib	CAPSULE;ORAL	213217-001	Nov 14, 2019		DISCN	Yes	No
Beone Medicines Usa	BRUKINSA	zanubrutinib	CAPSULE;ORAL	213217-001	Nov 14, 2019		DISCN	Yes	No
Beone Medicines Usa	BRUKINSA	zanubrutinib	TABLET;ORAL	218785-001	Jun 10, 2025		RX	Yes	Yes			Y	Y
Beone Medicines Usa	BRUKINSA	zanubrutinib	TABLET;ORAL	218785-001	Jun 10, 2025		RX	Yes	Yes
Beone Medicines Usa	BRUKINSA	zanubrutinib	CAPSULE;ORAL	213217-001	Nov 14, 2019		DISCN	Yes	No			Y
Beone Medicines Usa	BRUKINSA	zanubrutinib	TABLET;ORAL	218785-001	Jun 10, 2025		RX	Yes	Yes
Beone Medicines Usa	BRUKINSA	zanubrutinib	TABLET;ORAL	218785-001	Jun 10, 2025		RX	Yes	Yes			Y	Y

International Patents for BRUKINSA

When does loss-of-exclusivity occur for BRUKINSA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

China

Eurasian Patent Organization

European Patent Office

Israel

Japan

Mexico

New Zealand

Singapore

South Africa

South Korea

Spain

Taiwan

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering BRUKINSA around the world.

Country	Patent Number	Title	Estimated Expiration
Hungary	E065528
China	118252927
Cyprus	2022004
South Korea	101793807
Mexico	384627	FORMA CRISTALINA DE (S)-7-(1-ACRILOILPIPERIDIN-4-IL)-2-(4-FENOXIFE NIL)-4,5,6,7-TETRA-HIDROPIRAZOLO[1,5-A]PIRIMIDIN-3-CARBOXAMIDA, PREPARACION Y USOS DE LA MISMA. (CRYSTALLINE FORM OF (S)-7-(1-ACRYLOYLPIPERIDIN-4-YL)-2-(4-PHENOXY PHENYL)-4,5,6,7-TETRA-HYDROPYRAZOLO[1,5-A]PYRIMIDINE-3-CARBOXAMI DE, PREPARATION, AND USES THEREOF.)
New Zealand	751418	Crystalline form of (s)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof
Israel	325562

Supplementary Protection Certificates for BRUKINSA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2989106	4/2022	Austria		PRODUCT NAME: ZANUBRUTINIB ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/21/1576 (MITTEILUNG) 20211123
2989106	C20220008 00459	Estonia		PRODUCT NAME: ZANUBRUTINIIB;REG NO/DATE: EU/1/21/1576; 23.11.2021
2989106	202240004	Slovenia		PRODUCT NAME: ZANUBRUTINIB AND ITS PHARMACEUTICALLY ACCEPTABLE SALT; NATIONAL AUTHORISATION NUMBER: EU/1/21/1576; DATE OF NATIONAL AUTHORISATION: 20211122; AUTHORITY FOR NATIONAL AUTHORISATION: EU
2989106	C02989106/01	Switzerland		FORMER OWNER: BEIGENE SWITZERLAND GMBH, CH
2989106	PA2022504,C2989106	Lithuania		PRODUCT NAME: ZANUBRUTINIBAS ARBA FARMACINIU POZIURIU PRIIMTINA JO DRUSKA ; REGISTRATION NO/DATE: EU/1/21/1576 20211121
2989106	CR 2022 00008	Denmark		PRODUCT NAME: ZANUBRUTINIB ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/21/1576 20211123
2989106	2290500-4	Sweden		PRODUCT NAME: ZANUBRUTINIB OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REG. NO/DATE: EU/1/21/1576 20211123

BRUKINSA (Zanubrutinib): Investment Scenario, Market Dynamics, and Financial Trajectory

Last updated: February 3, 2026

---

Executive Summary

BRUKINSA (zanubrutinib) is a Bruton's tyrosine kinase (BTK) inhibitor developed by BeiGene for treating B-cell malignancies. Since its FDA approval in November 2019 for mantle cell lymphoma (MCL), BRUKINSA has rapidly gained market share in hematologic oncology. This report analyzes its investment landscape, market dynamics influencing its growth, and potential financial trajectory up to 2030. It integrates competitive positioning, regulatory outlooks, manufacturing considerations, and commercialization strategies to inform stakeholders' decision-making.

---

1. Investment Overview

Aspect	Detail
Therapeutic Area	Oncology - B-cell lymphomas, chronic lymphocytic leukemia (CLL), Waldenström’s macroglobulinemia (WM)
Regulatory Approvals	USFDA (Nov 2019), China (Nov 2021), EMA (pending/conditional), other emerging markets
Market Entry Year	2019
Market Cap (as of Q4 2022)	~$15 billion (BeiGene)
Main Competitors	Imbruvica (ibrutinib), Calquence (acalabrutinib), others
Pricing Model	Premium for targeted therapies; tiered based on regional reimbursement policies

Investment Risks:

• Competition from first-generation BTK inhibitors (ibrutinib, acalabrutinib)
• Patent expirations and biosimilar challenges
• Geopolitical/regulatory uncertainties, especially in China and US
• Clinical trial outcomes impacting indications expansion

Opportunities:

• Rapidly expanding indications (e.g., Marginal Zone Lymphoma (MZL), Chronic Graft-versus-host Disease (cGVHD))
• Increasing adoption in China and emerging markets
• Strategic collaborations and licensing agreements

---

2. Market Dynamics Impacting BRUKINSA

A. Therapeutic Market Landscape

Segment	Estimated 2022 Market Size	Growth Rate (CAGR 2022-2030)	Key Drivers
Chronic Lymphocytic Leukemia (CLL)	$8.2 billion	7.4%	Rising incidence, better survival rates
Mantle Cell Lymphoma (MCL)	$2.1 billion	6.9%	FDA approvals, expanded indications
Waldenström’s Macroglobulinemia (WM)	$1.3 billion	7.2%	Increasing diagnosis rates
Other B-cell Malignancies	$1.4 billion	8.1%	Clinical trials, label expansion

Source: EvaluatePharma, 2022.

B. Competitive Positioning

Competitor	Market Share (2022)	Strengths	Weaknesses
ibrutinib (Imbruvica)	55%	First-to-market; broad approval	Side effect profile; resistance issues
acalabrutinib (Calquence)	20%	Improved safety, FDA approvals in multiple lines	Higher cost, narrower indications
BRUKINSA (Zanubrutinib)	15%	Fewer off-target effects; favorable safety profile	Relatively newer, lower brand recognition

Note: Market share data approximate; varies regionally.

C. Regulatory and Reimbursement Environment

• US: CMS reimbursement policies favor targeted therapies with proven safety
• China: Lower drug pricing pressures, rapid approval process for innovative drugs
• Europe: Conditional approvals, national health authority reimbursement negotiations

D. Patent and Intellectual Property Outlook

Patent Category	Expiry Year	Risks
Composition of Matter Patent	2028-2032	Patent cliffs approaching in key markets
Method of Use Patents	2025-2027	Potential challenges, open-label biosimilar entry

---

3. Financial Trajectory and Forecasting

A. Revenue Projections (2023-2030)

Year	Estimated Global Revenue (USD Millions)	CAGR	Assumptions
2023	$1,200	—	Post-launch stabilization, initial launches
2024	$2,200	83%	Expanded indications, ramp-up in China
2025	$3,500	59%	Broader adoption, regulatory approvals in Europe and Asia
2026	$5,000	43%	Peak of current indications, pipeline launches
2027	$6,200	24%	Additional indications, combination therapies
2028	$7,500	21%	Patent expiry impacts, biosimilars enter
2029	$8,000	7%	Market saturation, competitive price pressures
2030	$8,500	6%	Mature market, pipeline contributions

Note: Assumes steady growth driven by indication expansion and regional penetration.

B. Cost Structure

Cost Type	Estimated Percentage of Revenue	Key Drivers
R&D	15-20%	Pipeline development, clinical trials
Manufacturing	10-12%	Scale-up costs, quality control
Sales & Marketing	20-25%	Global launch activities, coverage expansion
Regulatory & Legal	5-7%	Approvals, patent litigation, compliance

C. Investment and Funding Outlook

• BeiGene's latest funding rounds (2021-2022) raised ~$1.5B
• Focus on scaling manufacturing capacity (~20%) planned for 2023-2024
• Strategic collaborations with global pharma (e.g., Novartis, BeiGene partnerships) enhance liquidity and accelerate commercialization

---

4. Comparative Analysis: BRUKINSA vs. Competitors

Parameter	BRUKINSA	Ibrutinib (Imbruvica)	Acalabrutinib (Calquence)
Approval Year	2019	2013	2017
Indications	MCL, CLL, WM, MZL, cGVHD	MCL, CLL, WM	CLL, MCL
Safety Profile	Favorable, less bleeding risk	Higher adverse events	Similar safety to BRUKINSA
Pricing Strategy	Premium, region-dependent	Premium	Premium
Market Penetration	Rapid in China, emerging in US	Established globally	Growing in US, EU

---

5. Regulatory and Market Access Strategies

Strategy Element	Implementation Details	Expected Impact
Indication Expansion	Accelerate clinical development for MZL, CLL relapse	Broaden revenue streams
Regional Approvals	Leverage Chinese CDE pathways, EMA conditional approvals	Faster access in emerging markets
Pricing & Reimbursement	Engage early with payers, demonstrate cost-effectiveness	Improve coverage and sales potential
Pipeline Enhancement	Invest in combination therapies, new indications	Sustain revenue growth long-term

---

6. Key Drivers and Risks for Investment

Drivers	Risks
Increasing approval of expanded indications	Competition from biosimilars or next-generation inhibitors
Growing usage in China and Asia	Market saturation in core indications
Favorable safety profile enhancing adoption	Regulatory delays or rejection in new markets
Pipeline advancements	Clinical trial failures or safety concerns

---

7. Deep Comparison: Market Penetration and Key Differentiators

Factor	BRUKINSA	Competitors
Safety	Lower bleeding risks, fewer off-target effects	Similar, but higher adverse events for ibrutinib
Indication Breadth	Multiple B-cell malignancies, pipeline expanding	Similar, with some delayed approvals
Market Penetration	Rapid in China, emerging in US/Europe	Established early, slower growth
Pricing	Competitive, region-specific	Premium, with rebates varying

---

Frequently Asked Questions (FAQs)

Q1: What is the clinical advantage of BRUKINSA over earlier BTK inhibitors?
BRUKINSA exhibits fewer off-target effects, notably reduced bleeding and atrial fibrillation risks, facilitating broader and safer use, especially in elderly populations.

Q2: How is BRUKINSA expected to expand its indications?
Clinical trials are underway for MZL, CLL post-venetoclax, and cGVHD, aiming to secure regulatory approvals that could significantly boost sales.

Q3: What regional growth opportunities exist for BRUKINSA?
China remains a primary growth driver due to pricing flexibility and faster regulatory pathways. Europe and emerging markets are also expanding with broader indications and increasing adoption.

Q4: How does patent expiry impact BRUKINSA's future revenues?
Patents protecting the core molecule expire between 2028-2032; post-expiry, biosimilar competition could suppress prices and revenues, necessitating pipeline diversification.

Q5: Which competitive threats could undermine BRUKINSA’s market position?
Entry of next-generation BTK inhibitors with superior safety or efficacy, biosimilar emergence, and competitive pipeline developments are key threats.

---

Key Takeaways

• Rapid Growth Trajectory: BRUKINSA is positioned for significant revenue gains through indication expansion and regional penetration, especially in China and the US.
• Competitive Edge: Superior safety profile and targeted indications favor adoption over older BTK inhibitors.
• Pipeline and Indication Expansion: Critical to prolong market exclusivity and revenue streams, with ongoing trials in key malignancies.
• Market Risks: Patent expirations, biosimilar entrants, and intense competition pose challenges, mitigated by ongoing innovation and strategic collaborations.
• Investment Opportunity: High-growth potential balanced against regulatory and competitive risks; vigilance on pipeline milestones and regional market developments is essential.

---

References

[1] EvaluatePharma, 2022. "Hematology & Oncology Market Report."
[2] BeiGene Official Filings, 2022. "Annual Report."
[3] USFDA, 2019. "BRUKINSA (Zanubrutinib) Approval Letter."
[4] China NMPA, 2021. "Marketing Authorization for Zanubrutinib."
[5] MarketWatch, 2022. "BTK Inhibitors Market Analysis."